AI body scans could make chemo safer for women with ovarian and endometrial cancer

NCT ID NCT07144618

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests whether using an AI tool to analyze a patient's body composition from a CT scan can help doctors personalize chemotherapy dosing. The goal is to reduce severe side effects like low white blood cell counts in women with endometrial or ovarian cancer. About 294 participants will be randomly assigned to receive either standard dosing or AI-assisted dosing, and researchers will compare side effects, quality of life, and survival rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Paclitaxel (chemotherapy)
What this could lead to
If successful, this could lead to a more personalized way to dose chemotherapy, reducing severe side effects like low white blood cell counts and improving quality of life for patients.
What could go wrong
This is an early-stage study (Phase NA) with 294 participants, so results may not apply to all patients. The AI tool's predictions might not consistently outperform standard dosing, and the study focuses on specific cancers and chemotherapy drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Cheng Kung University Hospital

    Tainan, 704, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.